Russell Investments Group
MGX icon

Russell Investments Group’s Metagenomi Therapeutics MGX Stock Holding History

Russell Investments Group’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,179
Closed -$5.6K – 4539
2026
Q1 		$5.6K Sell
4,179
-2,957
-41% -$4.59K ﹤0.01% 3878
2025
Q4 		$11.6K Hold
7,136
– – ﹤0.01% 3762
2025
Q3 		$16.9K Hold
7,136
– – ﹤0.01% 3636
2025
Q2 		$10.6K Buy
7,136
+2,802
+65% +$4.39K ﹤0.01% 3324
2025
Q1 		$5.89K Buy
4,334
+2,442
+129% +$5.82K ﹤0.01% 3320
2024
Q4 		$6.83K Buy
+1,892
New +$4.57K ﹤0.01% 3223

Other funds holding MGX

PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return
FAG
Fortitude Advisory Group Gig Harbor, Washington $262M AUM 42.09% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Russell Investments Group's MGX Position: Q2 2026 in Review

Russell Investments Group sold out of Metagenomi Therapeutics (MGX) in Q2 2026, closing a stake of 4,179 shares — an estimated $5.6K sold.

Russell Investments Group first reported a position in MGX in Q4 2024 and held it in 6 quarters. The position peaked at $16.9K in Q3 2025. 9 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

  • Russell Investments Group reported no remaining Metagenomi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Russell Investments Group sold 4,179 Metagenomi Therapeutics shares in Q2 2026, an estimated $5.6K.
  • Russell Investments Group first reported a position in Metagenomi Therapeutics in Q4 2024 and held it in 6 quarters.
  • Russell Investments Group's Metagenomi Therapeutics position peaked at $16.9K in Q3 2025.
  • 9 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.